Changho Choi1, Sandeep Ganji2, Akshay Madan1, Ralph DeBerardinis1, Bruce Mickey1, Craig R. Malloy1, Robert Bachoo1, Elizabeth A. Maher1
1University of Texas Southwestern Medical Center, Dallas, TX, United States; 2UT Southwestern Medical Center, Dallas, TX, United States
Following the finding of the production of 2-hydroxyglutarate (2HG) in IDH-mutated gliomas, several researchers reported in-vivo detection of this onco-metabolite by 1H-MRS. Although the role of 2HG associated with IDH mutation is well established for prognosis, how it can be used for improving the patient care is largely unknown. In this paper, using 2HG data from 30 patients obtained over time, we demonstrate that 2HG is a remarkably sensitive biomarker for monitoring the tumor growth/progression and response to treatment in patients.